Literature DB >> 16817668

Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis.

Darcy Cox1, Jerome Stone.   

Abstract

Difficulties with self-injection, including inabillity to self-inject, are common for individuals taking home-administered injectable medications. In relapsing-remitting multiple sclerosis (MS), all of the currently available disease-modifying medications are injectables marketed for self-injection. Problems with self-injection pose a barrier to treatment adherence for many patients. Clinicians at the University of California, San Francisco (UCSF) Multiple Sclerosis Center have developed a number of strategies to help patients who experience anxiety associated with self-injection. These strategies have been empirically tested and found to be effective and easily implemented by mental health professionals and nurses. This article offers case examples and discussion of the principles of the techniques developed at UCSF to remediate patients' difficulties with self-injection. Nurses are most often the healthcare providers responsible for training MS patients in self-injection and monitoring their compliance. Nurses who are familiar with these tools have the opportunity to have a significant positive impact on patient comfort, confidence, and, ultimately, successful long-term adherence to disease-modifying medications.

Entities:  

Mesh:

Year:  2006        PMID: 16817668     DOI: 10.1097/01376517-200606000-00005

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  35 in total

Review 1.  [Adherence to neurologic treatment. Lessons from multiple sclerosis].

Authors:  S Kern; H Reichmann; T Ziemssen
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

2.  Adherence to first-line disease-modifying therapy for multiple sclerosis in kuwait.

Authors:  Raed Alroughani; Anil Thussu
Journal:  Int J MS Care       Date:  2012

3.  The Combined Effect of Nursing Support and Adverse Event Mitigation on Adherence to Interferon Beta-1b Therapy in Early Multiple Sclerosis: The START Study.

Authors:  Suhayl Dhib-Jalbut; Clyde Markowitz; Payal Patel; Francis Boateng; Mark Rametta
Journal:  Int J MS Care       Date:  2012

4.  The evolving role of the multiple sclerosis nurse: an international perspective.

Authors:  Therese Burke; Sara Dishon; Lynn McEwan; Jennifer Smrtka
Journal:  Int J MS Care       Date:  2011

5.  [Coping training for patients with multiple sclerosis. Evaluation from a neurologic standpoint].

Authors:  S Twork; K H Schwermer; J Kugler
Journal:  Nervenarzt       Date:  2007-04       Impact factor: 1.214

6.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Authors:  Francesco Patti
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

Review 7.  Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.

Authors:  Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Journal:  Drug Des Devel Ther       Date:  2010-07-21       Impact factor: 4.162

8.  Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.

Authors:  Virginia Devonshire; Txomin Arbizu; Bjorn Borre; Michael Lang; Alessandra Lugaresi; Barry Singer; Elisabetta Verdun di Cantogno; Peter Cornelisse
Journal:  BMC Neurol       Date:  2010-04-30       Impact factor: 2.474

Review 9.  Development of oral cladribine for the treatment of multiple sclerosis.

Authors:  Hans-Peter Hartung; Orhan Aktas; Bernd Kieseier; Giancarlo Comi Giancarlo Comi
Journal:  J Neurol       Date:  2010-02       Impact factor: 4.849

Review 10.  Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.

Authors:  Jerold Chun; Hans-Peter Hartung
Journal:  Clin Neuropharmacol       Date:  2010 Mar-Apr       Impact factor: 1.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.